Zorginstituut Nederland

> Return address PO Box 320, 1110 AH Diemen

To the Minister of Health, Welfare and Sport
PO Box 20350
2500 EJ THE HAGUE

2023046399

National Health Care Institute
Care
Medicinal Products

Willem Dudokhof 1
1112 ZA Diemen
PO Box 320
1110 AH Diemen
www.zorginstituutnederland.nl
info@zinl.nl

T +31 (0)20 797 85 55

Contact
Ms M. de Vries
warcg@zinl.nl

Our reference
2023046399

Date 12 December 2023
Re: Package advice tezepelumab (Tezspire®), continued

Dear Mr Kuipers,

In my letter of 16 August 2023 [ref. 2023030600] I have already informed you of the outcome of our assessment of the medicinal product tezepelumab (Tezspire®) indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma that is inadequately controlled despite a high dose inhaled corticosteroids in combination with another medicinal product for maintenance treatment.

The outcome of the substantive assessment has therefore already been shared with you. We concluded that tezepelumab meets the criteria of established medical science and medical practice for the aforementioned indication. The National Health Care Institute has recently been in consultation with the physicians association and the health insurers on the wording of the List 2 conditions. This letter concerns the additional advice on the inclusion of tezepelumab on List 1B of the Health Insurance Regulation (Rzv).

Further conditions
The National Health Care Institute has discussed the formulation of the further conditions for the inclusion of tezepelumab in the GVS with the health insurers and the NVALT.

Advice
The National Health Care Institute advises you to include tezepelumab for the aforementioned indication on List 1B of the GVS. The List 2 conditions shall be as followed:

Further condition of tezepelumab:
Only for an insured person as an add-on maintenance treatment for patients with severe eosinophilic asthma, severe IgE-mediated asthma, severe evident type 2 asthma or severe non-evident type 2 asthma that is inadequately controlled, despite high-dose inhaled corticosteroids in combination with another medicinal product for maintenance treatment.

The treatment should be carried out in the hospital during at least the first 6 months.

Yours sincerely,

Sjaak Wijma
Chairperson of the Executive Board

National Health Care Institute
Care
Medicinal Products

Date
12 December 2023

Our reference
2023046399